Mainz

Mainz Biomed is a molecular genetics diagnostic company specializing in the development of non-invasive early cancer detection tests. The company's flagship product, ColoAlert, is a highly sensitive, easy-to-use stool-based DNA test for colorectal cancer currently marketed across Europe and undergoing a pivotal clinical trial for FDA approval in the United States. Mainz Biomed is also expanding its pipeline to include diagnostic solutions for other gastrointestinal cancers, such as pancreatic cancer, leveraging its proprietary mRNA biomarker technology. By integrating advanced molecular biology with user-friendly testing kits, the company aims to improve screening compliance and early intervention outcomes.